A top chef says the drug that killed his appetite made him love food more, not less.
Quick Take
- Portland chef Gregory Gourdet says two years on tirzepatide cut his impulsive snacking and late-night eating while sharpening his hunger for bold, nutrient-packed meals.
- Clinical research backs the appetite-suppressing mechanism behind his experience, including slowed digestion and lower calorie intake at meals.
- Wider studies on GLP-1 drugs confirm reduced cravings and food intake, but stop short of proving a broad cultural shift toward healthier eating.
- Industry data already shows GLP-1 users buying fewer processed snacks, hinting at real changes in grocery carts and menus.
A Chef’s Two-Year Experiment With His Own Appetite
Gregory Gourdet, a James Beard Award-winning chef, wrote in Men’s Health that tirzepatide reshaped how he eats. He said the drug has worked for two years straight. The “extra bites,” the sweets eaten out of boredom, and the tired late-night snacking all faded. “That behavior has largely disappeared,” he wrote.
Gourdet didn’t describe losing interest in food. He described the opposite. He said he now enjoys food more and, when real hunger hits, craves meals built from protein, vegetables, grains, spice, and acid, the kind of cooking that satisfies both the stomach and the palate. For a chef, that distinction between eating out of habit and eating with intention carries real weight.
His account lines up with how tirzepatide is designed to work. The drug mimics gut hormones that signal fullness to the brain, and it slows how fast food leaves the stomach. A 2025 review of the science found that this combination reliably lowers hunger, increases fullness, and cuts prospective food intake, with one study showing nearly 350 fewer calories eaten at a single test meal.
What the Research Actually Shows About Appetite and Taste
A federally registered clinical trial protocol built specifically to study tirzepatide’s effect on gastric emptying used standard tools, visual scales measuring hunger, fullness, and desire to eat, to track these changes under controlled conditions. That kind of structured measurement is exactly what gives Gourdet’s personal account scientific footing, even though his story itself is anecdotal.
Medical literature explains why slower digestion changes eating behavior. When the stomach empties more slowly, the brain receives fullness signals for longer, which naturally reduces how much a person wants to eat at the next sitting. That mechanism explains reduced hunger. It does not, by itself, prove that people turn toward better-quality meals once they are eating less.
Broader reviews across GLP-1 drugs echo this pattern. Several studies report reduced cravings for sweets and fatty foods, alongside lower energy intake overall, but researchers caution that results vary a lot depending on how studies are designed and measured. The honest read is this: appetite suppression is well documented, while a true shift toward flavor-seeking, nutrient-focused eating is still an open question backed mostly by individual stories rather than large trials.
The Market Is Already Reacting, Even If the Science Is Still Catching Up
Wall Street is watching closely. Consumer analysts have pointed to survey data showing GLP-1 users are already buying fewer high-calorie, processed snacks and drinking less alcohol, changes significant enough to worry food and beverage companies about shrinking demand for their core products. One industry survey found weight management remains the top reason people start these drugs, confirming the motivation is squarely physical, not culinary.
None of this proves restaurants will reinvent their menus or that home cooks will suddenly crave bolder spice blends because of a weekly injection. What it does show is a measurable behavior shift already showing up in sales data and survey results, running alongside Gourdet’s personal account of eating less but enjoying it more. Whether that adds up to a changed food culture, or simply a changed grocery list, is the real question still worth watching.
Side effects matter here too. Slowed digestion that boosts fullness can also bring nausea, bloating, and reflux, symptoms that may push some users away from large or rich meals for reasons that have nothing to do with culinary taste. Gourdet’s experience reads as a positive outlier worth taking seriously, not yet a verdict on where American eating habits are headed next.
Sources:
menshealth.com, eprints.gla.ac.uk, link.springer.com, cdn.clinicaltrials.gov
